A Phase II Study of Tosedostat in Combination With Either Cytarabine or Decitabine in Newly Diagnosed AML or High-Risk MDS

Trial Profile

A Phase II Study of Tosedostat in Combination With Either Cytarabine or Decitabine in Newly Diagnosed AML or High-Risk MDS

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Tosedostat (Primary) ; Cytarabine; Decitabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Jan 2014 Status changed from suspended to recruiting. The partial clinical hold on tosedostat has been lifted and studies underway may continue, according to a Cell Therapeutics media release.
    • 10 Dec 2013 Interim results presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top